% | $
Quotes you view appear here for quick access.

Momenta Pharmaceuticals Inc. Message Board

perryfinker 2 posts  |  Last Activity: Jan 24, 2015 4:05 PM Member since: Jul 14, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    For those with ramp up panic syndrome

    by oshinator54 Jan 24, 2015 3:07 PM
    perryfinker perryfinker Jan 24, 2015 4:05 PM Flag

    Also, everyone keeps leaving out the party that ESRX v-pak Rxs are not being reported per a contractual obligation. So the real Rx # so far is 180 + that ESRX #.

  • Reply to

    Script numbers

    by ruby2626 Jan 9, 2015 1:31 PM
    perryfinker perryfinker Jan 10, 2015 11:35 AM Flag

    IMS is underreprting V-Pak Rx data:

    Those watching the launch through weekly prescription data from IMS Health (NYSE:IMS) were stymied by IMS' announcement that some of the prescriptions were not being reported due to "a contractual condition between a supplier and the manufacturer," and thus are being underreported, according to RBC Capital Markets analyst Michael Yee. Yee noted that sales of Viekira's competitors, Gilead Sciences' (NASDAQ:GILD) Harvoni and Sovaldi, were continuing in line with expectations for the two weeks after the Viekira launch, and were on track to do at least $12 billion this year.

19.39-0.49(-2.46%)May 26 4:00 PMEDT